MERCK KGAA
🇩🇪Germany
- Country
- 🇩🇪Germany
- Ownership
- Public
- Established
- 1668-01-01
- Employees
- 62.9K
- Market Cap
- $84.2B
- Website
- http://www.merckgroup.com/de
A Observational, Prospective Study to Assess the Impact of Fatigue in the Quality of Life of Patients With Multiple Sclerosis in Argentina
Completed
- Conditions
- Multiple Sclerosis, Relapsing-remitting
- First Posted Date
- 2010-03-03
- Last Posted Date
- 2014-03-07
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 71
- Registration Number
- NCT01080001
- Locations
- 🇦🇷
Hospital Fernandez de Buenos Aires, Capital federal, Buenos Aires, Argentina
To Identify and Evaluate the Predictive Factors for Depression in Patients Diagnosed With Multiple Sclerosis
Completed
- Conditions
- Multiple Sclerosis
- First Posted Date
- 2010-03-03
- Last Posted Date
- 2014-07-31
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 301
- Registration Number
- NCT01079975
- Locations
- 🇦🇷
Instituto de Investigacion Neurológica (Uruguay 840), Capital Federal, Buenos Aires, Argentina
To Assess the Prevalence of Spasticity and the Impact on the Quality of Life in Multiple Sclerosis Patients
Completed
- Conditions
- Multiple Sclerosis, Relapsing Remitting
- First Posted Date
- 2010-03-03
- Last Posted Date
- 2013-10-16
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 150
- Registration Number
- NCT01080040
- Locations
- 🇦🇷
Fundación Rosarina de Neurorehabilitación, Rosario, Argentina
Correlation Between Multiple Sclerosis Functional Composite (MSFC) and Expanded Disability Status Scale (EDSS) in Patients With Multiple Sclerosis (MS) in Argentina
Completed
- Conditions
- Multiple Sclerosis
- First Posted Date
- 2010-03-03
- Last Posted Date
- 2013-10-16
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 252
- Registration Number
- NCT01080014
- Locations
- 🇦🇷
Dr. Roberto Rosa, Buenos Aires, Argentina
Sexual Dysfunction, Disability and Quality of Life in Patients With Multiple Sclerosis (MS)
Completed
- Conditions
- Multiple Sclerosis, Relapsing Remitting
- First Posted Date
- 2010-03-03
- Last Posted Date
- 2013-10-16
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 306
- Registration Number
- NCT01080053
- Locations
- 🇦🇷
Dr. Norma Deri, Buenos Aires, Argentina
Safety, Tolerability and Adherence With Rebif® New Formulation in Real Life Settings (STAR)
Completed
- Conditions
- Multiple Sclerosis, Relapsing Remitting
- First Posted Date
- 2010-03-03
- Last Posted Date
- 2014-07-31
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 254
- Registration Number
- NCT01080027
- Locations
- 🇬🇷
Neurology Clinic, General Hospital of Thessaloniki "G. Papanikolaou", Thessaloniki, Greece
A Post Marketing Surveillance Study of Cetuximab in Patients With Squamous Cell Carcinoma of Head and Neck (SCCHN)
Completed
- Conditions
- Carcinoma, Squamous Cell of Head and Neck
- Interventions
- Other: No Intervention
- First Posted Date
- 2010-03-03
- Last Posted Date
- 2014-07-08
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 215
- Registration Number
- NCT01080066
- Locations
- 🇨🇳
Liouying Chi-Mei Hospital, Liouying, Tainan County, Taiwan
A Post-marketing Surveillance Study on Erbitux in Combination With Platinum-based Chemotherapy in Metastatic/Recurrent Squamous Cell Cancer of the Head and Neck
Withdrawn
- Conditions
- Neoplasms, Squamous Cell
- First Posted Date
- 2010-02-25
- Last Posted Date
- 2014-07-02
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Registration Number
- NCT01075841
Determine the Improvement in Activity Status/Quality of Life (QoL) of Patients With Rheumatoid Arthritis (RA) During Treatment With Lodotra (Prednisone)
- First Posted Date
- 2010-02-25
- Last Posted Date
- 2014-02-19
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 2728
- Registration Number
- NCT01075711
- Locations
- 🇩🇪
Merck Serono GmbH, Darmstadt, Germany, Darmstadt, Germany
Prospective, Post Marketing Surveillance Study On Erbitux® (Cetuximab) in Patients With Locally Advanced or Recurrent and/or Metastatic Squamous Cell Cancer of the Head and Neck in Korea
Completed
- Conditions
- Head and Neck Cancer
- First Posted Date
- 2010-02-25
- Last Posted Date
- 2014-08-29
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 221
- Registration Number
- NCT01075828
- Locations
- 🇰🇷
Chungnam National University Hospital, Jung-gu Daejeon, Korea, Republic of
© Copyright 2025. All Rights Reserved by MedPath